Skip to main content
Clinical Trials/NCT07546461
NCT07546461Enrolling By InvitationNot Applicable

A Multiphase Operational and Environmental Assessment of Lunar Surface Habitation, Lunar Gateway Transit Systems, and Acceleration Pathways for Sustained Human Habitation of the Martian Surface

Truway Health, Inc.1 site in 1 country30 target enrollmentStarted: June 26, 2026Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Enrolling By Invitation
Sponsor
Enrollment
30
Locations
1
Primary Endpoint
Habitat System Resilience Index (HSRI)

Study Overview

Brief Summary

This study evaluates the operational, environmental, and habitation-system requirements for sustained human presence on the lunar surface, the performance of the Lunar Gateway as a transit and staging architecture, and the pathways required to accelerate readiness for Martian surface habitation. The protocol examines habitat resilience, radiation exposure modeling, life-support continuity, EVA logistics, behavioral health in isolated environments, and systems-engineering workflows across lunar, transit, and Mars-analog environments. Special emphasis is placed on the identification, extraction, processing, and utilization of lunar water-ice deposits as a critical resource for life-support, radiation shielding, and in-situ propellant production. Findings will inform future mission design, habitation module development, and interplanetary operational frameworks.

Detailed Description

This multiphase observational and operational protocol investigates the habitation lifecycle across three mission environments: (1) lunar surface habitation systems, (2) Lunar Gateway transit architecture, and (3) Martian surface analog habitats. The study integrates engineering, environmental, behavioral, and operational assessments to characterize requirements for long-duration human habitation beyond Earth orbit, with a specific focus on the role of water-ice resources in sustaining habitation and enabling interplanetary logistics.

The lunar surface phase evaluates habitat stability, environmental control and life-support system (ECLSS) resilience, radiation shielding performance, EVA logistics, mobility constraints, and dust mitigation strategies. A central component of this phase is the assessment of lunar water-ice availability, extraction feasibility, thermal stability, and processing pathways. Water-ice is evaluated as a source for potable water, oxygen generation, hydrogen production, and in-situ propellant manufacturing. Operational workflows, redundancy models, and failure-mode responses are analyzed to determine the feasibility of sustained lunar habitation supported by local resource utilization.

The Lunar Gateway phase examines transit-architecture performance, including docking operations, crew systems behavior, resource transfer workflows, and the continuity of life-support and environmental systems during transit. The study evaluates how water-ice-derived consumables from the lunar surface could be staged, processed, or transferred through the Gateway to support outbound missions. Behavioral health observations and operational stressors are assessed to understand crew performance in confined transit environments.

The Martian surface analog phase focuses on long-duration isolation, dust intrusion mitigation, power redundancy, habitat resilience, and environmental stability under Mars-analog conditions. This phase evaluates the translational pathways required to accelerate readiness for Martian habitation, including the potential use of Martian subsurface ice deposits for life-support, radiation shielding, and fuel production. Comparisons between lunar and Martian ice-resource utilization inform cross-environment operational strategies.

Across all phases, the protocol collects operational, environmental, and systems-engineering data to inform future mission architectures, habitation module design, and interplanetary habitation strategies. The study does not involve FDA-regulated products, biomedical interventions, or human subjects research as defined by federal regulations. All activities occur within controlled operational and engineering environments.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Adults aged 18-65
  • Able to participate in isolated, confined, or controlled operational environments
  • Prior experience in engineering, environmental systems, analog missions, or mission operations
  • Ability to perform EVA-analog tasks and operational workflows
  • Willingness to participate in multi-phase lunar, transit, and Mars-analog simulations

Exclusion Criteria

  • Medical or physical limitations that prevent participation in isolated or operational environments
  • Conditions that limit safe participation in EVA-analog tasks
  • Inability to comply with operational protocols or safety requirements
  • Participation in conflicting operational studies

Arms & Interventions

Lunar Surface Habitation Cohort

Participants assigned to evaluate lunar surface habitation systems, including habitat stability, ECLSS performance, radiation shielding, EVA logistics, and water-ice extraction workflows.

Intervention: Habitat Systems Evaluation (Other)

Lunar Gateway Transit Cohort

Participants assigned to assess Lunar Gateway transit operations, including docking workflows, resource transfer, life-support continuity, and staging of water-ice-derived consumables.

Intervention: Habitat Systems Evaluation (Other)

Lunar Gateway Transit Cohort

Participants assigned to assess Lunar Gateway transit operations, including docking workflows, resource transfer, life-support continuity, and staging of water-ice-derived consumables.

Intervention: Water-Ice Resource Utilization Assessment (Other)

Martian Surface Analog Cohort

Participants assigned to operate within Mars-analog habitats to evaluate long-duration isolation, dust mitigation, power redundancy, and utilization pathways for Martian subsurface ice.

Intervention: Habitat Systems Evaluation (Other)

Martian Surface Analog Cohort

Participants assigned to operate within Mars-analog habitats to evaluate long-duration isolation, dust mitigation, power redundancy, and utilization pathways for Martian subsurface ice.

Intervention: Water-Ice Resource Utilization Assessment (Other)

Martian Surface Analog Cohort

Participants assigned to operate within Mars-analog habitats to evaluate long-duration isolation, dust mitigation, power redundancy, and utilization pathways for Martian subsurface ice.

Intervention: EVA and Mobility Operations (Other)

Lunar Surface Habitation Cohort

Participants assigned to evaluate lunar surface habitation systems, including habitat stability, ECLSS performance, radiation shielding, EVA logistics, and water-ice extraction workflows.

Intervention: Water-Ice Resource Utilization Assessment (Other)

Lunar Surface Habitation Cohort

Participants assigned to evaluate lunar surface habitation systems, including habitat stability, ECLSS performance, radiation shielding, EVA logistics, and water-ice extraction workflows.

Intervention: EVA and Mobility Operations (Other)

Outcomes

Primary Outcomes

Habitat System Resilience Index (HSRI)

Time Frame: 36 months

HSRI is a composite scale (0-100) assessing environmental stability, ECLSS uptime (%), redundancy activation success rate (%), and mean time to recovery (hours). Higher scores indicate better habitat resilience.

Water-Ice Utilization Efficiency Ratio

Time Frame: 36 months

Efficiency ratio (%) measured using the Water-Ice Processing Performance Scale (WIPPS; 0-100%), quantifying the proportion of extracted ice converted into usable water, oxygen, hydrogen, and propellant. Higher values indicate greater efficiency.

Radiation Modeling Accuracy Score

Time Frame: 36 months

Accuracy score (%) comparing predicted radiation dose (mSv) to measured dose using the Habitat Radiation Monitoring System (HRMS). Higher scores indicate greater predictive accuracy.

Secondary Outcomes

  • EVA Task Completion Time(36 months)
  • EVA Mobility Constraint Score(36 months)
  • Dust Intrusion Index(36 months)
  • Life-Support Continuity Score (LSCS)(36 months)
  • Behavioral Health Stability Index (BHSI)(36 months)
  • Power System Uptime Percentage(36 months)
  • Redundancy Activation Success Rate(36 months)
  • Power Recovery Time(36 months)
  • Particulate Intrusion Reduction Score(36 months)
  • Abrasion Resistance Index(36 months)
  • Operational Degradation Rate(36 months)
  • Transit-to-Surface Operational Continuity Score (TSOCS)(36 months)

Investigators

Sponsor
Truway Health, Inc.
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Active, not recruiting
Not Applicable
A Phase IV, Multi-Center, Active-Controlled, Observer-Blind Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture (Optaflu®) or in Embryonated Hen Eggs (Agrippal®) in Adults and Elderly With and Without Underlying Medical Conditions, and to Evaluate the Immunogenicity in a Subset of Subjects With Underlying Medical Conditions.no medical condition: healthy subjects
EUCTR2007-002872-32-DEovartis Vaccines and Diagnostics S.r.l.
Active, not recruiting
Not Applicable
An open, multi-centre, phase IIIb, long term follow-up study to assess the safety, tolerability and efficacy of once-daily oral modified-release hydrocortisone in patients with adrenal insufficiency.
EUCTR2008-003990-42-SEDuoCort Pharma AB86
Active, not recruiting
Phase 1
Safety and Efficacy of peripheral blood stem cell transplantation using specifically purified stem cell preparations derived from patient family members in paediatric and adult patientsHematological and non-hematological malignancies, and non-malignant diseases, requiring allogeneic blood stem cell transplantation without available HLA-identical donor.MedDRA version: 18.1 Level: PT Classification code 10063581 Term: Stem cell transplant System Organ Class: 10042613 - Surgical and medical procedures
EUCTR2011-005562-38-DEMiltenyi Biotec GmbH60
Active, not recruiting
Phase 1
Safety and Efficacy of peripheral blood stem cell transplantation using specifically purified stem cell preparations derived from patient family members in paediatric and adult patientsHematological and non-hematological malignancies, and non-malignant diseases, requiring allogeneic blood stem cell transplantation without available HLA-identical donor.MedDRA version: 18.1 Level: PT Classification code 10063581 Term: Stem cell transplant System Organ Class: 10042613 - Surgical and medical procedures
EUCTR2011-005562-38-NLMiltenyi Biotec GmbH60
Active, not recruiting
Phase 1
A PHASE 3, MULTICENTER, LONG-TERM OBSERVATIONAL STUDY OF SUBJECTS FROM TANEZUMAB STUDIES WHO UNDERGO A TOTAL KNEE, HIP OR SHOULDER REPLACEMENT
EUCTR2013-002549-12-GBPfizer Inc.,211
A Multiphase Operational and Environmental... | Clinical Trial